Results 51 to 60 of about 53,892 (275)

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Pattern of calcification on CT and FDG-PET of a rare perineural mantle cell lymphoma: a potential of non-histological imaging marker [PDF]

, 2016
The presence of calcification in a particular FDG-avid soft tissue lesion may at times present uncertainty regarding the clinical course of the disease pathology. Calcific deposits are not specific for either benign or malignant aetiologies (Brant et al.,
Ahmad Saad, Fathinul Fikri, Nordin, Abdul Jalil, Shakher, Ramdave   +2 more
core  

Mechanisms of spinal glial activation in chemotherapy‐induced peripheral neuropathy: Focus on microglia and astrocytes

Ibrain, EarlyView.
Chemotherapy‐induced peripheral neuropathy (CIPN) remains a major clinical challenge, with central sensitization considered an important pathological mechanism in its occurrence and persistence. This review focuses on spinal astrocytes and microglia, systematically summarizing the pathological mechanisms of spinal glial cells involved in CIPN caused by
Long Gu, Song Cao, Yonghuai Feng
wiley   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

International Journal of Cancer, EarlyView.
What's New? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Caroline E. Dietrich   +5 more
wiley   +1 more source

Mantle cell lymphoma presented as enteric intussusception and involved gallbladder

Journal of Cancer Research and Practice, 2017
Intussusception caused by a lymphomatous mass is extremely rare in adults. To date, only four cases of mantle cell lymphoma have intussusception as a treatment sequelae or complication.
Chih-Ching Chin, Junping Shiau, Wei-Ciao Wu   +2 more
doaj   +1 more source

CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies [PDF]

, 2016
Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are
Ahmadzadeh, V., Farajnia, S., Safdari, Y.   +2 more
core   +1 more source

A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐NHL

British Journal of Haematology, EarlyView.
Bone marrow (BM) involvement in B‐cell non‐Hodgkin lymphoma (B‐NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high‐throughput 3D BM co‐culture model that faithfully reproduces key tumour–stroma interactions.
Alex Zadro, Alberto Arribas, Maria Vittoria Colombo, Eleonora Cannas, Filippo Spriano, Luciano Cascione, Afua Adjeiwaa Mensah, Federico Simonetta, Dalila Petta, Christian Candrian, Chiara Arrigoni, Francesco Bertoni, Matteo Moretti   +12 more
wiley   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients

British Journal of Haematology, EarlyView.
Summary The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum‐based salvage chemotherapy at the University
Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Laurens Sillje, Joost Kluiver, Anke van den Berg, Wouter Plattel, Arjan Diepstra, Marcel Nijland   +9 more
wiley   +1 more source